- Home
- ACRE vs ELDN Comparison
ACRE vs ELDN Comparison
Compare ACRE & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | ELDN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 229.3M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACRE | ELDN |
|---|---|---|
| Price | $4.85 | $2.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.33 | ★ $8.50 |
| AVG Volume (30 Days) | 399.1K | ★ 1.3M |
| Earning Date | 05-06-2026 | 03-19-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | 26.17 | ★ 30.67 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.02 | N/A |
| P/E Ratio | $3.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $1.35 |
| 52 Week High | $5.89 | $4.60 |
Technical Indicators
Market Signals| Indicator | ACRE | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 50.42 |
| Support Level | $4.85 | $2.48 |
| Resistance Level | $5.10 | $2.77 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 54.67 | 11.21 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.